Illumina, Inc. (ILMN)

Market Cap	21.57B
Revenue (ttm)	4.39B
Net Income (ttm)	-1.59B
Shares Out	158.60M
EPS (ttm)	-9.98
PE Ratio	n/a
Forward PE	32.85
Dividend	n/a
Ex-Dividend Date	Jun 25, 2024

Volume	14,036,300
Open	133.45
Previous Close	134.00
Day's Range	133.23 - 137.69
52-Week Range	97.36 - 156.66
Beta	1.11
Analysts	Buy
Price Target	162.67 (+19.59%)
Earnings Date	Feb 6, 2025

About ILMN

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regio...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jul 28, 2000
• Employees: 13,360
• Stock Exchange: NASDAQ
• Ticker Symbol: ILMN
• Website: https://www.illumina.com

Financial Performance

In 2023, Illumina's revenue was $4.50 billion, a decrease of -1.75% compared to the previous year's $4.58 billion. Losses were -$1.16 billion, -73.64% less than in 2022.

Analyst Forecast

According to 19 analysts, the average rating for ILMN stock is "Buy." The 12-month stock price forecast is $162.67, which is an increase of 19.59% from the latest price.

Price Target

$162.67

(19.59% upside)

Analyst Consensus: Buy